YÜKSEL, S. Et Al. 2016. First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients. PEDIATRIC DRUGS , vol.18, no.6 , 413-420.

YÜKSEL, S., Evrengul, H., ÖZÇAKAR, Z. B., Becerir, T., Yalcin, N., Korkmaz, E., ... ÖZALTIN, F.(2016). First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients. PEDIATRIC DRUGS , vol.18, no.6, 413-420.

YÜKSEL, SELÇUK Et Al. "First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients," PEDIATRIC DRUGS , vol.18, no.6, 413-420, 2016

YÜKSEL, SELÇUK Et Al. "First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients." PEDIATRIC DRUGS , vol.18, no.6, pp.413-420, 2016

YÜKSEL, S. Et Al. (2016) . "First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients." PEDIATRIC DRUGS , vol.18, no.6, pp.413-420.

@article{article, author={SELÇUK YÜKSEL Et Al. }, title={First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients}, journal={PEDIATRIC DRUGS}, year=2016, pages={413-420} }